<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941419</url>
  </required_header>
  <id_info>
    <org_study_id>PADUJCTC</org_study_id>
    <nct_id>NCT02941419</nct_id>
  </id_info>
  <brief_title>Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis</brief_title>
  <official_title>Safety and Efficacy of Platelet Lysate for Therapeutic Angiogenesis in Patients With Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of autologous angiogenesis in patients with critical limb ischemia using platelet&#xD;
      lysate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten male and female patients diagnosed with Peripheral artery disease (PAD), will be&#xD;
      recruited. This diagnosis will be based on medical history, physical examinations, laboratory&#xD;
      tests, and specific diagnostic tests. Patients qualified for this study, are patients with&#xD;
      distal extremity ischemia indicated by claudication and rest pain present for a minimum of 4&#xD;
      weeks without evidence of improvement in response to conventional drug therapy; showed&#xD;
      angiographic evidence of PAD in the affected limb; and were not candidates for surgical&#xD;
      revascularization. Platelet lysate will be injected intramuscularly at different sites of the&#xD;
      gastrocnemius muscle. The purpose of this study is to evaluate the safety and efficacy of&#xD;
      platelet lysate injections into ischematic limbs of patients with PAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2013</start_date>
  <completion_date type="Actual">February 9, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment the safety of platelet lysate injection</measure>
    <time_frame>6 months</time_frame>
    <description>Patients will be assessed for any relevant adverse event resulting from the platelet lysate injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment the efficacy of platelet lysate injection</measure>
    <time_frame>6 months</time_frame>
    <description>Assessing the therapeutic benefit of all four platelet lysate injections by ankle brachial index (ABI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Platelet lysate injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of platelet lysate intramuscularly in the gastrocnemius muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet lysate</intervention_name>
    <description>Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease</description>
    <arm_group_label>Platelet lysate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Competent and willing to give informed consent, and to be available for all baseline&#xD;
             treatment and follow up examinations required by the protocol.&#xD;
&#xD;
          -  Gender: Male or female.&#xD;
&#xD;
          -  Established Peripheral arterial disease, clinically and hemodynamically confirmed as&#xD;
             per Rutherford 3, 4 and&#xD;
&#xD;
          -  History of intermittent claudication for &gt; eight weeks.&#xD;
&#xD;
          -  Limited exercise due to moderate to severe claudication.&#xD;
&#xD;
          -  Resting ankle brachial index (ABI) &lt; 0.85, toe pressure ≤ 60 mm Hg, Toe brachial index&#xD;
             (TBI) &lt;0.6, or Trans-cutaneous oxygen pressure (TcPO2) ≤ 60 mmHg in the foot.&#xD;
&#xD;
          -  Not eligible for surgical or radiological revascularization.&#xD;
&#xD;
          -  In case of diabetic patients, he/she should be on medication and fairly controlled&#xD;
             (HbA1c &lt;10%).&#xD;
&#xD;
          -  Normal liver enzymes, serum creatinine &lt; 1.4&#xD;
&#xD;
          -  Normal platelet count.&#xD;
&#xD;
          -  On regular medication for hypertension if any.&#xD;
&#xD;
          -  No evidence of malignancy&#xD;
&#xD;
          -  Low Questionnaire scores.&#xD;
&#xD;
          -  Body mass index &lt;30.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with child bearing potential, pregnant and lactating women.&#xD;
&#xD;
          -  Rheumatoid Arthritis.&#xD;
&#xD;
          -  History of neoplasm or malignancy in the past 10 years.&#xD;
&#xD;
          -  Reported unstable cardiovascular disease, heart failure or symptomatic postural&#xD;
             hypotension within 6 months before screening.&#xD;
&#xD;
          -  Leg edema&#xD;
&#xD;
          -  Inflammatory or progressive fibrotic disorder&#xD;
&#xD;
          -  Renal insufficiency or failure&#xD;
&#xD;
          -  History of infectious disorder.&#xD;
&#xD;
          -  Chronic inflammatory disease&#xD;
&#xD;
          -  History of stroke or myocardial infarction ( &lt; 3 months).&#xD;
&#xD;
          -  Bleeding or clotting disorder, use of oral anticoagulant therapy (heparin, warfarin).&#xD;
&#xD;
          -  Lab values for&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dl.&#xD;
&#xD;
          -  Platelet count &lt;100,000.&#xD;
&#xD;
          -  Prothrombin time/ partial thromboplastin time (PT/PTT)&gt; 3 seconds.&#xD;
&#xD;
          -  Alanine aminotrasferase (ALT) and aspartatet aminotrasferase (AST) &gt; 1.5x of the&#xD;
             normal lab value.&#xD;
&#xD;
          -  Creatinine ≥ 1.4&#xD;
&#xD;
          -  Poorly controlled diabetes (HbA1c ≥10)&#xD;
&#xD;
          -  Bilirubin &gt; 1.5x of the normal lab value.&#xD;
&#xD;
          -  Systemic autoimmune disease.&#xD;
&#xD;
          -  Receiving immunosuppressant medications.&#xD;
&#xD;
          -  Uncontrolled hypertension or hypotension.&#xD;
&#xD;
          -  Abdominal aortic aneurism &gt; 5 cm.&#xD;
&#xD;
          -  Active or untreated Tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Moath AlSmady</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Platelet lysate</keyword>
  <keyword>Critical limb ischemia</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

